FTC hits Amneal, Impax and Endo with antitrust suit
28-01-2021
Impax to divest 10 products amid acquisition by Amneal
30-04-2018
Amneal and Impax merge to become ‘fifth largest’ generics company
19-10-2017
parbradyphoto / iStockphoto.com
The US Federal Trade Commission (FTC) has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FTC, , Federal Trade Commission, generics, Amneal Pharmaceuticals, Impax Laboratories, mergers and acquisitions, M&S, anticompetitive
